在西班牙纳瓦拉地区异常高的肺炎发病率,2023-2024年
Camino Trobajo-Sanmartín1, María Eugenia Portillo2, Ana Navascués3
1Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain.
在2023-2024赛季内,纳瓦拉的肺炎发病率急剧上升,总体增加了73%,儿童病例急剧增加. 这一激增与肺炎球菌和Mycoplasma pneumoniae感染的增加有关.
科学领域:
- 流行病学 流行病学
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 全球范围内,肺炎仍然是一个重大的公共卫生问题.
- 了解季节性发病模式对于有效的公共卫生干预至关重要.
- 特定的病原体,如肺炎链球菌和 Mycoplasma pneumoniae 是肺炎的常见原因.
研究的目的:
- 为了确定2023-2024赛季在西班牙纳瓦拉的肺炎发病率.
- 分析临床肺炎,肺炎球菌抗原阳性病例和Mycoplasma pneumoniae PCR阳性病例的趋势.
- 为了将这些利率与以前的赛季进行比较,特别是2017-2018年和2018-2019年.
主要方法:
- 利用电子医疗记录进行数据收集.
- 评估了不同年龄组的肺炎发病率.
- 追踪的特定病因病原体:肺炎链球菌和肺炎神经质菌.
主要成果:
- 在2023-2024赛季,整体肺炎发病率比2017-2018/2018-2019赛季的平均水平增加了73%.
- 在5至14岁的年龄组中,肺炎发病率增加了4.43倍.
- 确诊的肺炎球菌肺炎增加了63%,而Mycoplasma pneumoniae病例增加了19倍.
结论:
- 在2023-2024赛季,所有年龄群体的肺炎发病率异常高.
- 观察到的增加与肺炎球菌和Mycoplasma pneumoniae感染的显著增加有关.
- 这些发现凸显了持续监测和公共卫生战略的潜在调整的必要性.
更多相关视频
03:53Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
相关概念视频
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-III
